Royalty Report: Drugs, cardiac, Therapeutic – Collection: 178134


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Drugs
  • cardiac
  • Therapeutic
  • Disease
  • Pharmaceuticals
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 178134

License Grant
Licensor grants the exclusive right in the Territory to bucindolol product improvements (e.g., sustained release formulation, improved or new indications, formulations and strengths), contingent upon Licensee reimbursing Licensor for costs relating to clinical trials and other tests conducted primarily for benefit of the Territory and 1/3 of all other development costs which have a worldwide benefit, including any previous product improvement development costs incurred by Licensor.
License Property
Bucindolol is a drug currently in Phase III clinical trials for congestive heart failure ('CHF' or 'heart failure').
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 152350

License Grant
Licensor hereby assigns all of its rights under the Knoll Agreement to Licensee, and Licensee hereby assumes and agrees to perform, pay and discharge all of Licensees and Licensors obligations under the Knoll Agreement arising after the date of this Agreement, as such relate to the development or commercialization of Bucindolol or the Product in the Knoll Territory.
License Property
Product means Bucindolol and any finished product containing Bucindolol as the active ingredient.

Bucindolol means the compound Benzonitrile, 2-[2-hydroxy-3-[[2-(1H-indol-3-yl)-1,1-imethylethyl]amino]propoxy]-, monohydrochloride, also known under the trademark 'BEXTRA'.

Bucindolol Intellectual Property means the Trademarks and any patents, patent applications, copyrights, know-how, processes, formulae, data (including, but not limited to, preclinical, clinical, and marketing data) and trade secrets relating to the manufacture, development, commercialization or use of Bucindolol including any Improvement made or acquired by Licensor during the term of this Agreement.

BEAT means the Bucindolol Evaluation in Acute Myocardial Infarction Trial being conducted by Knoll.

BEST means the 'Beat-blocker Evaluation of Survival Trial' being conducted by the National Institutes of Health and the Veterans Administration, evaluating the use of Bucindolol in treating patients with congestive heart failure.

Trademark means the registered trademark BEXTRA(R), any other trademark, trade name or service mark used as a product identifier for Bucindolol and any variations thereof, in each case, whether or not registered.

Field of Use
'Field' means use of Bucindolol as a pharmaceutical therapy for congestive heart failure and/or left ventricular dysfunction.

IPSCIO Record ID: 328142

License Grant
The University grants
–  an exclusive license to make, have made, use, sell, offer to sell and import the Know-How in the Territory and within the Fields of Use; and,
–  an exclusive license of University’s Patent Rights, except for Patent Rights in University Case No. 2002.026H, in the Territory to make, have made, use, sell, offer to sell, and import any Licensed Products in the Fields of Use and to practice any Licensed Processes in the Fields of Use; and
–  an exclusive license of University’s Patent Rights in University Case No. 2002.026H in the Territory to make, have made, use, sell, offer to sell and import any Licensed Products in the Fields of Use and to practice any Licensed Process in the Fields of Use.
License Property
Licensor has rights to technology relating to expression profiling in the intact human heart and a method of treating heart failure with bucindolol.

Bucindolol means the beta-adrenergic–receptor antagonist having the chemical formula 2-{2-hydroxy-
3{{2-(3-indolyl)-1,1-dimethylethyl}amino}propoxy}-benzonitrile hydrochloride, and its racemates, isomers, prodrugs, active metabolites, analogs and any pharmaceutically acceptable salt or complex thereof, and diagnostics used in connection with its prescription.

Bucindolol Invention shall mean an Invention relating solely to the use of Bucindolol as a therapeutic or as a diagnostic used solely in connection with the development of Bucindolol.

Patents are titled
Expression Profiling in the Intact Human Heart,
Methods for Treating Heart Failure with Bucindolol Based on Genetic Targeting of the Alpha-le Adrenergic
Methods for Treating Heart Failure with Bucindolol Based on Genetic Targeting of the Beta-1 Adrenergic
     Receptor, and,
Methods for Treatment with Bucindolol Based on Genetic Targeting.

Field of Use
Fields of use is all fields.

Licensee is focused on developing and commercializing genetically-targeted therapies for heart failure and other cardiovascular diseases.

IPSCIO Record ID: 28684

License Grant
The Licensor is developing a cell therapy for the treatment of cardiovascular disease.

The Merger Agreement requires the Licensee to pay certain earn out payments following the first commercial sale of AMR-001 for the benefit of the former stockholders of the Licensor.

License Property
The Licensor's lead compound, AMR-001, now represents the Licensee's most clinically advanced therapeutic and has commenced enrollment for a Phase 2 trial to investigate AMR-001’s efficacy in preserving heart function after a heart attack.
Field of Use
The Licensee also expects to begin a Phase 1 clinical trial by 2013 to investigate AMR-001’s utility in arresting the progression of congestive heart failure and the associated comorbidities of that disease.

IPSCIO Record ID: 995

License Grant
Under the terms of its strategic License Agreement with the Licensor holding ownership rights to certain clinical trial data of Gencaro, the Licensee will incur milestone and royalty obligations upon the occurrence of certain events.
License Property
GencaroTM (bucindolol hydrochloride) is a pharmacologically unique beta-blocker and mild vasodilator for chronic heart failure, or HF. Gencaro was the subject of a Phase 3 heart failure mortality trial involving more than 2,700 patients and was unique in gathering DNA data on over 1,000 of its participants.
Field of Use
The rights granted apply to the healthcare industry relating to heart failure.

IPSCIO Record ID: 359108

License Grant
Canadian Licensor granted Licensee the sole, exclusive, irrevocable license to patented nanotechnologies for use with any drugs including cannabinoids,  to develop and optimize a proprietary nanoformulation of pharmaceutical cannabidiol, designed to avoid first-pass metabolism and improve bioavailability, for the treatment of heart failure.
License Property
Nanotechnologies are designed to improve solubilization, pharmacokinetics, and drug targeting of lipophilic drugs. Nanotechnologies is the use of matter on an atomic, molecular, and supramolecular scale for industrial purposes.

Cannabidiol is a non-psychoactive molecule with broad therapeutic potential in the treatment of chronic inflammatory disease including heart failure.

Field of Use
The license to patented nanotechnologies is for use with any drugs or classes of drugs currently used or developed in the future to diagnose or treat heart failure and/or any cardiovascular disease and/or cardiopulmonary disease and/or cardiac arrhythmias.

Field of use to treat cardiovascular disease, cardiopulmonary disease, and cardiac arrhythmias.

IPSCIO Record ID: 7393

License Grant
The Licensor has entered into a License Agreement with the Licensee, of Moscow Russia, giving that firm License rights to ERCs (Endometrial Regenerative Cells) for CHF (Congestive Heart Failure) indications in the territory of Russia.
Licensor acknowledges that he has the exclusive right to use the know-how, the exclusive right to permit other persons to use it, and the exclusive right to prevent any unauthorised disclosure and (or) other use of this know-how, and is entitled to dispose of its at his discretion in compliance with the above specified rights.
License Property
In January 2012, the Licensor announced the initiation of the RECOVER-ERC (Non-Revascularizable IschEmic Cardiomyopathy treated with Retrograde Coronary Sinus Venous Delivery of Cell Therapy) Phase II clinical trial.

Regenerative medicine is the process of replacing or regenerating human cells, tissues or organs to restore or establish normal function.

Field of Use
The Licensee is providing sponsorship and funding for ongoing Phase II clinical trial in CHF being conducted at the Bakulev Scientific Center for Cardiovascular Surgery.

IPSCIO Record ID: 26860

License Grant
The Company acquired exclusive rights from Licensor, an individual, to a United States patent issued in September 1989, covering a method of reducing mortality associated with chronic CHF in patients with impaired cardiac function by administering a combination of specified amounts of hydralazine and isosorbide dinitrate.
License Property
BIDIL® – an oral dosage formulation containing the combination of hydralazinehydrochloride and isosorbide dinitrate (two generically available vasodilators) – subject to FDA approval, as to which no assurance can be given, proposed to be used to improve symptoms and survival in patients with congestive heart failure (CHF) who are inappropriate for treatment with angiotensin – converting enzyme (ACE) inhibitors.
Field of Use
In March 1993, the Company submitted to the FDA an IND to commence human bioequivalency studies in the U.S.  Phase III clinical testing has been completed.

IPSCIO Record ID: 27897

License Grant
Under the terms of its strategic License Agreement with the licensor, who holds ownership rights to certain clinical trial data of Gencaro, the licensee will incur milestone and royalty obligations upon the occurrence of certain events.
License Property
Gencaro is a beta-blocker and mild vasodilator indicated for the treatment of heart failure and other indications.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.